K2 Principal Fund, L.P. Alnylam Pharmaceuticals, Inc. Transaction History
K2 Principal Fund, L.P.
- $201 Million
- Q1 2025
A detailed history of K2 Principal Fund, L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 30,100 shares of ALNY stock, worth $9.14 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
30,100Holding current value
$9.14 Million% of portfolio
0.23%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
720Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.09 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$3.97 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.9 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.17 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.34 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $37.4B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...